Cytogen Corp. is taking partnering discussions for its ProstaScint imaging agent down to the wire. While most companies like to have a marketing partner in place significantly ahead of FDA approval in order to plan both pre-launch and launch activities, CYTO is still concluding discussions with a partner that will take the lead in marketing ProstaScint to urologists if and when FDA approves the product.

The unanimous endorsement of ProstaScint last week by the FDA's Medical Imaging Drugs Advisory Committee (MIDAC) adds urgency to the negotiations. According to CYTO spokesperson Pam Murphy, the timing and strategy for the launch will not be determined until a marketing deal is finalized.